ID30250A - Kemoterapi kombinasi - Google Patents

Kemoterapi kombinasi

Info

Publication number
ID30250A
ID30250A IDW00200101616A ID20011616A ID30250A ID 30250 A ID30250 A ID 30250A ID W00200101616 A IDW00200101616 A ID W00200101616A ID 20011616 A ID20011616 A ID 20011616A ID 30250 A ID30250 A ID 30250A
Authority
ID
Indonesia
Prior art keywords
combination chemotherapy
chemotherapy
combination
Prior art date
Application number
IDW00200101616A
Other languages
English (en)
Indonesian (id)
Inventor
Richard Car Ton Gowan
Judith S-Leopold
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ID30250A publication Critical patent/ID30250A/id

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Seasonings (AREA)
IDW00200101616A 1998-12-22 1999-12-21 Kemoterapi kombinasi ID30250A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11329198P 1998-12-22 1998-12-22
US16478899P 1999-11-10 1999-11-10

Publications (1)

Publication Number Publication Date
ID30250A true ID30250A (id) 2001-11-15

Family

ID=26810891

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101616A ID30250A (id) 1998-12-22 1999-12-21 Kemoterapi kombinasi

Country Status (31)

Country Link
EP (1) EP1140291B1 (et)
JP (1) JP2002532570A (et)
KR (1) KR20010099877A (et)
CN (1) CN1333698A (et)
AP (1) AP2001002175A0 (et)
AT (1) ATE310567T1 (et)
AU (1) AU2203900A (et)
BG (1) BG105715A (et)
BR (1) BR9916839A (et)
CA (1) CA2352326A1 (et)
CZ (1) CZ20012139A3 (et)
DE (1) DE69928568T2 (et)
EA (1) EA200100687A1 (et)
EE (1) EE200100339A (et)
ES (1) ES2253928T3 (et)
GE (1) GEP20043172B (et)
HK (1) HK1042057A1 (et)
HR (1) HRP20010473A2 (et)
HU (1) HUP0104844A3 (et)
ID (1) ID30250A (et)
IL (1) IL143939A0 (et)
IS (1) IS5969A (et)
MA (1) MA26768A1 (et)
NO (1) NO20013099L (et)
NZ (1) NZ512859A (et)
OA (1) OA11733A (et)
PL (1) PL348326A1 (et)
SK (1) SK8712001A3 (et)
TR (1) TR200101871T2 (et)
WO (1) WO2000037141A1 (et)
YU (1) YU45401A (et)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230251B1 (hu) 2000-07-19 2015-11-30 Warner-Lambert Co. 4-Jód-fenil-amino-benzhidroxámsav-észter-származékok és ezeket tartalmazó gyógyászati készítmények
US20020054869A1 (en) 2000-09-01 2002-05-09 Han-Mo Koo Inhibition of mitogen-activated protein kinase (MAPK) pathway: a selective therapeutic strategy against melanoma
WO2002076496A1 (en) * 2001-03-22 2002-10-03 Van Andel Institute Anthrax lethal factor inhibits tumor growth and angiogenesis
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
CZ20022216A3 (cs) * 2001-07-02 2003-05-14 Warner-Lambert Company Kombinační chemoterapie
CA2542012A1 (en) * 2003-10-08 2005-04-21 Teijin Pharma Limited A method for producing aminopyrrolidine derivatives and intermediate compounds
EP1682495A1 (en) 2003-10-21 2006-07-26 Warner-Lambert Company LLC Polymorphic form of n- (r)-2,3-dihydroxy-propoxy -3,4-d ifluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
SI1802579T1 (sl) * 2004-10-20 2014-03-31 Merck Serono Sa Derivati 3-arilaminopiridina
CN1807413B (zh) * 2005-09-28 2010-05-05 中国医学科学院医药生物技术研究所 咔唑磺酰胺衍生物及其制备方法
BRPI0617165B1 (pt) 2005-10-07 2023-10-03 Exelixis Inc Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
WO2007054556A1 (de) 2005-11-11 2007-05-18 Æterna Zentaris Gmbh Neue pyridopyrazine und deren verwendung als modulatoren von kinasen
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
CN111643496A (zh) 2006-12-14 2020-09-11 埃克塞利希斯股份有限公司 使用mek抑制剂的方法
EP2370568B1 (en) 2008-12-10 2017-07-19 Dana-Farber Cancer Institute, Inc. Mek mutations conferring resistance to mek inhibitors
EP3028699B1 (en) 2010-02-25 2018-03-21 Dana-Farber Cancer Institute, Inc. Braf mutations conferring resistance to braf inhibitors
AU2011224410B2 (en) 2010-03-09 2015-05-28 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
CN103301096B (zh) * 2012-03-14 2015-05-06 中国中化股份有限公司 取代二苯胺类化合物作为制备抗肿瘤药物的应用
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
CN104837826B (zh) 2012-10-12 2018-07-27 埃克塞里艾克西斯公司 制备用于治疗癌症的化合物的新型方法
WO2014133071A1 (ja) * 2013-02-27 2014-09-04 第一三共株式会社 Mapkシグナル伝達経路を阻害する化合物に対する応答性を予測する方法
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
CN111909053B (zh) * 2020-08-06 2022-12-06 湖北省生物农药工程研究中心 基于二芳胺单元的酰胺类衍生物及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1997032604A1 (en) * 1996-03-07 1997-09-12 Novartis Ag Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds
AU5610398A (en) * 1997-02-28 1998-09-18 Warner-Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
AU6580598A (en) * 1997-03-21 1998-10-20 Board Of Regents, The University Of Texas System (noey2) gene compositions and methods of use
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6040321A (en) * 1997-11-12 2000-03-21 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
US5959097A (en) * 1998-11-20 1999-09-28 Isis Pharmaceuticals, Inc. Antisense modulation of MEK2 expression

Also Published As

Publication number Publication date
DE69928568D1 (de) 2005-12-29
PL348326A1 (en) 2002-05-20
EP1140291A1 (en) 2001-10-10
DE69928568T2 (de) 2006-07-27
CZ20012139A3 (cs) 2002-01-16
AU2203900A (en) 2000-07-12
EA200100687A1 (ru) 2001-12-24
WO2000037141A1 (en) 2000-06-29
SK8712001A3 (en) 2002-02-05
MA26768A1 (fr) 2004-12-20
WO2000037141A9 (en) 2000-12-07
NO20013099L (no) 2001-08-20
OA11733A (en) 2005-05-12
GEP20043172B (en) 2004-02-25
HUP0104844A2 (en) 2002-06-29
NZ512859A (en) 2004-06-25
IL143939A0 (en) 2002-04-21
AP2001002175A0 (en) 2001-06-21
ATE310567T1 (de) 2005-12-15
BR9916839A (pt) 2001-10-09
BG105715A (en) 2002-04-30
IS5969A (is) 2001-06-14
YU45401A (sh) 2004-07-15
TR200101871T2 (tr) 2001-10-22
ES2253928T3 (es) 2006-06-01
HRP20010473A2 (en) 2002-08-31
HUP0104844A3 (en) 2003-05-28
EP1140291B1 (en) 2005-11-23
CN1333698A (zh) 2002-01-30
JP2002532570A (ja) 2002-10-02
NO20013099D0 (no) 2001-06-21
CA2352326A1 (en) 2000-06-29
HK1042057A1 (zh) 2002-08-02
KR20010099877A (ko) 2001-11-09
EE200100339A (et) 2002-10-15

Similar Documents

Publication Publication Date Title
DE69916556D1 (de) Bohrhülsensysteme
FI980567A0 (fi) Radiofrekvensfoerstaerkare
NO20010382D0 (no) Agglutineringsundersökelse
DE69910192D1 (de) Kabeltrommel
DE69940286D1 (de) Brenstoffzellenstapel
FI980536A (fi) Kokoonpanolinja
NO20013099D0 (no) Kombinasjonskjemoterapi
ID24739A (id) Senyawa-senyawa
DE69902762D1 (de) Riser-spannanordnung
ID24221A (id) Tempat patrum
DE69916308D1 (de) Hydroboronationsverfahren
DK1124809T3 (da) Benzoylpyridaziner
DE69919644D1 (de) Wellenabstreifdichtung
DE69936434D1 (de) Bildverabeitungsvorrichtung
FI980564A0 (fi) Volymregleringsorgan foer stroemningsroer
DE69924068D1 (de) Gasfederfüllventil
DE69941474D1 (de) Lichtstrahlabtastgerät
DE69933674D1 (de) Nagigationsvorrichtung
NO20006616D0 (no) Propionibacteriumvektor
DE69922235D1 (de) Mehrfachflüssigelektrosprühschnittstelle
DE69942000D1 (de) Sicherheitstontaube
NO20004740L (no) Paroksetinblandinger
DE69917377D1 (de) Siphonanordnungen
ATA32198A (de) Beschlag
FI981980A (fi) Vaahdotuskennolinja